Rejected at 1:41 a.m. Jan, 18, 2024 ] by Cameron
Author: sameern
Related Note: 1473986179822
Rationale for change

Page 32 of Pathoma under III. Immune Thrombocytopenic Purpura part A days "Autoimmune production of IgG against platelet antigens (e.g., GPIIb/IIIa)". The card stated that it was against that receptor, but it is not specifically limited to the GPIIb/IIIa receptor, it can be towards any antigenic material of the platelet.

Rejection reason

Improper sourcing; see suggestion guidelines

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::05_Platelet_Disorders #AK_Step2_v12::#UWorld::COMLEX::101171 #AK_Step2_v12::!Shelf::Peds::no_dupes #AK_Step1_v12::#AMBOSS::#Self_Assessment #PANCE::HEME::coagulation_disorders #AK_Step1_v12::#Pathoma::04_Hemostasis::01_Primary_Hemostasis_&_Related_Bleeding_Disorders #AK_Step1_v12::#NBME::18 #PANCE::EOR::PEDS #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::01_Thrombocytopenia #AK_Step2_v12::#AMBOSS #AK_Step1_v12::#AMBOSS::ghaFW4 #AK_Step1_v12::#UWorld::COMLEX::25063 #AK_Step3_v12::#UWorld::5296 #AK_Step1_v12::#Pixorize::01_Biochemistry::18_Platelet_Disorders::05_Immune_Thrombocytopenic_Purpura_(ITP) #AK_Step2_v12::#UWorld::Step::4383 #AK_Step1_v12::#UWorld::Step::1954 #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::17_Platelet_disorders::*Immune_Thrombocytopenic_Purpura #AK_Other::!AK_UpdateTags::AnKing_Image::!Subjects::Hematology::Platelet_disorders #AK_Step2_v12::Original_decks::Zanki_Step_2::Peds::Step_1_Pediatrics #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::01_Bleeding_&_Clotting_Disorders::02_Bleeding_Disorders:_Platelet_Disorders_DDx #AK_Other::!AK_UpdateTags::AnKing_Image::Mujeeb::Platelet_disorders #AK_Step1_v12::^Systems::HemeOnc::Hematology #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::06_Platelets::03_Platelet_Disorders #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_Hematology #AK_Step1_v12::#NBME::21 #PANCE::EOR::Family_med #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step1_v12::#SketchyPath::09_Blood_&_Coagulation::03_Coagulopathies_&_Platelet_Disorders::01_Quantitative_Platelet_Disorders #AK_Step2_v12::#AMBOSS::eC0xIR #AK_Step2_v12::#Resources_by_rotation::Peds::step1_pediatrics_zanki #PANCE::EOR::IM #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::03_Antiplatelet,_Anticoagulant,_Thrombolytic_Agents #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::01_Primary_Hemostasis #AK_Step2_v12::#AMBOSS::CGaqYm